

# Accepted Manuscript

Nutrition and fasting mimicking diets in the prevention and treatment of autoimmune diseases and immunosenescence

In Young Choi, Changan Lee, Valter D. Longo



PII: S0303-7207(17)30055-2

DOI: [10.1016/j.mce.2017.01.042](https://doi.org/10.1016/j.mce.2017.01.042)

Reference: MCE 9815

To appear in: *Molecular and Cellular Endocrinology*

Received Date: 9 June 2016

Revised Date: 25 January 2017

Accepted Date: 25 January 2017

Please cite this article as: Choi, I.Y., Lee, C., Longo, V.D., Nutrition and fasting mimicking diets in the prevention and treatment of autoimmune diseases and immunosenescence, *Molecular and Cellular Endocrinology* (2017), doi: 10.1016/j.mce.2017.01.042.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# Nutrition and Fasting Mimicking Diets in the Prevention and Treatment of Autoimmune Diseases and Immunosenescence

In Young Choi,<sup>1,2</sup> Changhan Lee,<sup>1</sup> and Valter D. Longo<sup>1,3,4,5\*</sup>

<sup>1</sup>Longevity Institute, School of Gerontology, and Department of Biological Sciences, University of Southern California, Los Angeles, CA 90089, USA

<sup>2</sup>Department of Microbiology, Immunology, Molecular Genetics, University of California Los Angeles, Los Angeles, CA 90095, USA

<sup>3</sup>Department of Neuroscience, Dana and David Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, USA

<sup>4</sup>Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA

<sup>5</sup>IFOM, FIRC Institute of Molecular Oncology, 20139 Milan, Italy

\*Correspondence: vlongo@usc.edu

## Abstract

Complex and coordinated signals are necessary to initiate and sustain the activation, proliferation, and differentiation of lymphocytes. These signals, which are known to determine T-cell fate and function, also depend on the metabolic state of the organism. Recent studies indicate that both the type and levels of nutrients can influence the generation, survival and function of lymphocytes and therefore can affect several autoimmune diseases. Here, we review the dysregulation of lymphocytes during autoimmunity and aging, the mechanisms associated with loss of immune function, and how fasting mimicking diets and other dietary interventions affect autoimmunity and immunosenescence.

## Introduction

Aging is associated with a progressive functional decline of the immune system, commonly referred to as immunosenescence. There are several consequences of age-dependent

immunosenesence, including increased susceptibility to infection and autoimmune diseases, reduced response to vaccination, and chronic inflammation <sup>1,2</sup>. In general, men experience a stronger age-dependent alteration of immune function than women <sup>3</sup>.

T cells, which are derived from hematopoietic stem cells (HSCs), mature in the thymus. The T cell repertoire is generated in the thymus by TCR rearrangement, including the purging of thymocytes that recognize self-peptides via negative selection. Thymic activity progressively declines after puberty, and such involution has been thought to underline the age-dependent decline in T lymphocyte number/diversity and increase in autoimmunity <sup>4,5</sup>. However, recent evidence suggests that thymic involution itself may not be sufficient to account for the reduction of T cell repertoire and number <sup>6</sup>. Another cause of the age-dependent decline in the adaptive immune system is the age-dependent decline of HSC function <sup>6</sup>. Young HSCs possess a balanced potential to differentiate into myeloid and lymphoid lineage cells that later become components of the innate and adaptive immune system. However, aged HSCs preferentially give rise to myeloid cells rather than lymphoid cells, accompanied by a decline in common lymphoid progenitors (CLPs), and ultimately reduced T and B cell lymphogenesis that can cause stem cell exhaustion and reduced regenerative capacity <sup>7</sup>.

The rejuvenation of HSCs to reverse or postpone immunosenescence has recently received much attention <sup>6</sup>. Dietary restriction (DR) is an effective and reproducible intervention to increase healthy lifespan in various model organisms <sup>8,9</sup>. The major DR regimens include caloric restriction (CR) <sup>10</sup>, intermittent fasting (IF) <sup>9</sup>, time-restricted feeding (TRF) <sup>11-13</sup>, restriction of specific macronutrients <sup>8,14-16</sup>, ketogenic diets (KD), and periodic fasting (PF) or fasting-mimicking diets (FMDs) <sup>17</sup> (**Table 1**). However, studies of the effects of many dietary interventions on the immune system have yielded different results, with chronic calorie

restriction resulting in both positive and negative effects on the immune system and immune responses<sup>18</sup>. In addition, CR requires significant life-style changes, making them challenging to adhere to, especially for frail patients and older individuals. However, certain periodic dietary restrictions have the potential to prevent and/or reverse age-dependent immune dysfunction by killing autoimmune cells and activating HSC-dependent regeneration while minimizing the burden of the intervention and the side effects<sup>19-21</sup>. Here, we will discuss the potential of various DR regimens in the treatment of autoimmune diseases and the mechanisms that may mediate these effects.

### **Metabolism and Immune Response**

The immune system is tightly regulated by nutrient availability and metabolism<sup>22</sup>. Leukocytes utilize oxidative metabolism in a resting state, but upon activation they switch to a more anabolic state that relies on aerobic glycolysis, a process that converts glucose into lactate even in the presence of sufficient oxygen to support oxidative phosphorylation<sup>1,3,23</sup> (**Fig. 1**). The switch to glycolytic metabolism increases the availability of carbon sources which can be converted to biosynthetic precursors that required for cellular proliferation<sup>23</sup>. This metabolic reprogramming is, in part, regulated by hexokinase II<sup>24</sup> and the phosphoinositide 3-kinase (PI3K)-dependent glucose transporter Glut1<sup>25</sup>. Glut1 overexpression in mice resulted in an increase in not only the number of naïve T cells, but also the number of CD44<sup>high</sup> T cells (activated T cells)<sup>26</sup>. T-cell specific Glut1 deletion resulted in impaired CD4<sup>+</sup> T cell activation, clonal expansion and survival<sup>26</sup>. Amino acids, in particular glutamine, are key sources of biosynthetic precursors for activated T cells<sup>27,28</sup>. Upon activation, T cells increase the expression of glutamine transporters; conversely, glutamine transporter deletion impairs T effector cell differentiation<sup>27,28</sup>. Glutamine utilization, which requires ASC amino-acid transporter 2 (ASCT2), influences the development

and differentiation of pro-inflammatory Th1 and Th17 cells and also T cell receptor (TCR)-stimulated activation of the metabolic kinase mammalian target of rapamycin complex 1 (mTORC1)<sup>29</sup>. In a subsequent study, it was shown that proliferation and differentiation of T-cells upon activation require amino acid transporters, specifically system L transporter (Slc7a5) that mediates the uptake of large neutral amino acids (LNAAs)<sup>30</sup>. Loss of Slc7a5 reduces the proliferation and differentiation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells and promotes regulatory T cells (Treg). Deficient LNAA uptake due to loss of Slc7a5 leads to reduced c-Myc expression which is critical for boosting activation-induced glycolysis and glutaminolysis in T cells<sup>30,31</sup>. Moreover, intracellular leucine concentration can affect mTORC1 activation via regulating cytosolic branched chain aminotransferases (BCATc)<sup>32</sup>. BCATc expression was up-regulated in activated CD4<sup>+</sup> T cells, and BCATc deficiency led to increased intracellular leucine and enhanced mTORC1 activity and glycolytic phenotype<sup>32</sup>.

The importance of mTOR dependent T-cell fate has also emerged in recent years. The activation of mTOR, which is a catalytic subunit of mTORC1 and mTORC2, directs the proper activation and differentiation of effector CD4<sup>+</sup> T cells. Suppression of mTOR1 with rapamycin promoted the generation of FoxP3<sup>+</sup> Treg<sup>33</sup>, and T cell specific deletion of mTOR increased the production of Treg upon activation<sup>34</sup>. Interestingly, stimulation of HIF-1 activity, which is downstream of mTOR, shifted T cell differentiation into Th17, but deficiency of HIF-1 increased the generation of Treg cells. Consistently, Treg-specific deletion of raptor, an essential component of mTORC1, decreased the suppressive activity of Tregs *in vivo* and promoted the development of a fatal early onset inflammatory disorder<sup>34,35</sup>.

### **Metabolism in Autoimmune Diseases and Aging**

Autoimmune and allergic diseases (e.g. asthma, lupus, multiple sclerosis (MS), and rheumatoid arthritis (RA)) are characterized by dysfunctional lymphocytes and metabolic dysregulation. In asthma patients, CD4<sup>+</sup> T cells exhibit increased glycolysis, measured by increased lactate production levels<sup>36</sup>. Notably, naïve CD4<sup>+</sup> T cells from both asthma patients and a mouse asthma model resulted in higher amounts of lactate production upon stimulation, suggesting increased glycolysis<sup>36</sup>. The inhibition of glycolysis in CD4<sup>+</sup> T cells by dichloroacetate (DCA), an inhibitor of aerobic glycolysis blocked T cell activation and the development of asthma, while promoting IL-10 production and Treg differentiation<sup>36</sup>. In contrast, in a murine lupus model, splenocytes showed increased glucose oxidation level, possibly indicating an increased activity of the TCA cycle<sup>37</sup>. In a recent study, normalizing CD4<sup>+</sup> T cell metabolism by a combination treatment with metformin, a mitochondrial respiration inhibitor, and 2-deoxy-D-glucose (2DG), a glycolytic inhibitor, reversed disease biomarker in lupus-prone B6.*Sle1.Sle2.Sle3* (TC) mouse model and caused a reduction in IFN- $\gamma$  production *in vitro*<sup>38</sup>. In multiple sclerosis (MS), increased levels of glutamine and glutamate release have been detected at the site of demyelination and axonal degeneration, possibly correlating with disease severity<sup>39</sup>. CD4<sup>+</sup> T cells from MS patients showed an over-activation of the mTOR pathway<sup>40,41</sup> which may indicate a dysregulation of the amino acid sensing signaling supporting a significantly lower percentage of nTreg (natural regulatory T) cells observed in relapse-remitting MS (RRMS) patients<sup>42</sup>. In rheumatoid arthritis (RA), CD4<sup>+</sup> T cells from the patients failed to produce as much ATP and lactate as healthy control T cells even under proliferating condition<sup>43</sup>. In CD4<sup>+</sup> T cells from RA patients, the enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphate 3 (PFKFB3), which is a rate-limiting enzyme in the glycolytic pathway, was suppressed<sup>43</sup>. Dysfunction of PFKFB3 leads to impaired glycolytic flux, apoptosis-susceptibility, and increased reactive

oxygen species (ROS) production during T cell activation<sup>43</sup>. It was further confirmed that several glycolytic enzymes in the lymphocytes of RA patients, such as glucose-6-phosphate isomerase, aldolase and enolase, have been identified as antigens recognized by autoantibodies<sup>44-46</sup>.

In addition to autoimmune and inflammatory diseases, aging promotes immune dysfunction. Age largely affects the adaptive immune response, especially that based on T and B lymphocytes<sup>47-49</sup>. Immune cells in older organisms shows a skewed metabolism toward glycolysis, which is associated with immunosenescence<sup>50</sup>. Such age-dependent changes include a general decline of total T lymphocytes, with a significant reduction in the number and proportion of naïve T cells and both helper/inducer (CD4<sup>+</sup>) and suppressor/cytotoxic (CD8<sup>+</sup>) cells<sup>3,51,52</sup>. Also, the T lymphocyte repertoire, generated by excisional T cell receptor (TCR) gene rearrangement, diminishes with age as measured by TCR-rearrangement excision circles (TREC)<sup>53</sup> and the TCR signaling cascade, including Raf-1/MEK/ERK kinases, JNK protein kinase, ZAP-70 kinases, and Ca<sup>2+</sup> release, can be impaired in elderly people<sup>54</sup>. Contributing to immune dysfunction is also the reduced efficiency of the aged immune system in eliminating self-recognizing antibodies, increasing the incidence of autoimmunity resulting from the combination of dysfunctional T and B lymphocytes<sup>55,56</sup>.

### **Nutrition and Autoimmunities**

Different forms of dietary restrictions can increase lifespan and protect multiple aging systems<sup>17,57-62</sup>. However, the view that all types of dietary restriction can be somehow equivalent leading to similar changes, including those related to autoimmunities, is simplistic and probably incorrect. In fact, it is now clear that CR can be either effective or ineffective in promoting longevity or disease reduction depending on its dietary composition. For example, a study done by the National Institute on Aging (NIA) in 2012 shows that there are no significant health

benefits and no difference in life-span extension for caloric restricted rhesus monkeys, regardless of whether the CR regimen implemented in young or older age rhesus monkeys<sup>56</sup>. In contrast, another study done by the Wisconsin National Primate Research Center in 2014 shows improved survival associated with 30% CR initiated in adult rhesus monkey (7-14 years). In this study the *ad lib* control monkeys had a threefold increased risk of death and a risk of disease 2.9 times higher than that of the calorie-restricted monkeys<sup>62</sup>. These contrasting CR results on the longevity and the healthspan of monkeys may be due to differences in dietary composition and varying protein content which can have an impact on CR-induced cellular protection<sup>63</sup>. Thus, it is essential to begin to consider and discuss the effects of different forms of restriction, whether they involve calories or composition, separately and also use terminology and abbreviations that accurately identify the type of restriction, duration, and the mode of use. For example, CR is generally understood to describe a 20-40% restriction of calories below *ad libitum* levels, whereas DR is a much more inclusive term that can refer to the restriction of calories or of specific macronutrients<sup>8,64</sup> (**Table 1**). IF, which can also be interchangeable with alternate day feeding (ADF), instead refers to the alternation of a day of feeding and a day of either water only fasting or a very low calorie diet. In contrast, periodic fasting (PF) refers to two or more consecutive days of fasting that is done periodically; this can range from every week to every several months. These definitions and classifications are particularly important in the identification and understanding of the dietary interventions that affect autoimmunity since they can have drastically different, and in some cases opposite, effects on both immune cells and on the regeneration of cells and tissues damaged by the autoimmunity.

PF or a low protein and sugar and high fat 48 to 72 hours FMD, which provides calories in a quantity and form that does not interfere with the effects of water only fasting, can result in a

40% or greater decrease in serum glucose levels in rodents<sup>17</sup> and a 20% or greater decrease in serum glucose in humans<sup>58</sup>. During the initial fasting period, cells utilize liver glycogen as the main energy source, and then switch to a metabolic mode in which non-hepatic glucose, fat-derived ketone bodies and free fatty acids are used for energy<sup>58</sup>. PF also leads to a dramatic reduction in certain growth factors, particularly the insulin-like growth factor 1 (IGF-1), which is a key signaling molecule for cellular growth and an inhibitor of both cell protection and regeneration<sup>58</sup>. Some of the changes that are shared by chronic CR and PF in mice are reduced protein synthesis rate, reduced AKT activity<sup>65</sup> and mTOR/S6K activities, increased 4E-BP1 activity<sup>66</sup> and increased activity of FOXO transcription factors<sup>58, 67</sup> all of which have been implicated in both CR and PF-dependent longevity extension. These changes in metabolic sensing pathway upon CR and PF have shown to be clinically relevant for cancer treatment and prevention including potentially ameliorating several side effects cause by chemotherapy in humans<sup>68</sup>, and protection from chemotherapy-induced toxicity and sensitization from a range of cancer cells to chemotherapy in mice<sup>69,70</sup>. It is widely known that cancer cells rely more on glycolysis than on oxidative phosphorylation known as the Warburg effect. Fasting-based reduction in glucose but also in other nutrients and factors on which cancer cells rely, contribute to the increased cancer cells' sensitivity towards the chemotherapy<sup>64</sup>. As described in the previous sections, immune cells, during hyper-activation following antigen-specific T cell activation or during autoimmune response, utilize a similar strategy to generate the energy carriers and metabolic intermediates needed to produce biomass and inflammatory mediators<sup>71</sup>. Therefore, PF may kill cancer and immune cells, particularly the more active autoimmune cells, by partially overlapping mechanisms that are poorly understood.

## **Multiple Sclerosis**

MS is an autoimmune disorder characterized by T cell-mediated demyelination and neurodegeneration of the central nervous system (CNS)<sup>72-75</sup>, whose exact etiology remains unclear. The autoimmune view of MS is strongly supported by the use of the animal experimental autoimmune encephalomyelitis (EAE) model, which displays some of the key MS characteristics. For example, during the activation phase, the antigen presenting cells migrate to the lymph nodes and present the immunodominant peptide to naïve T cells<sup>76-79</sup>, and the histocompatibility (MHC) Class II-restricted CD4<sup>+</sup> T cells secrete many inflammatory cytokines such as IFN- $\gamma$ , TNF $\alpha$ , IL-6, and IL-17. During the effector phase, CD4<sup>+</sup> T cells that recognize antigen proliferate, cross the blood-brain barrier and subsequently activate macrophages and microglia<sup>80</sup> that cause demyelination, oligodendrocyte death, and axon degeneration. As the disease progresses, remyelination and regeneration of oligodendrocyte become inefficient and ultimately fail<sup>81,82</sup>, resulting in disease progression. Several MS treatment drugs have been effective in reducing immune responses, but their impact on long-term disease progression, accrual of irreversible neurological disability, and the function of the immune system remains largely unclear<sup>83</sup>. The limitation of pharmacological immune-modulating treatments is due to both the relatively non-specific inhibition of immune responses leading to immunosuppression and the failure to repair the damaged myelin in the affected tissues.

Although we are only beginning to understand the relationship between nutrients, fasting and autoimmune disorders, the dietary treatment of MS and other autoimmune diseases has high potential, since it may stimulate and take advantage of the ability of the organism to repair and replace its damaged cells without interfering with the function of normal cells and systems.

### **Dietary Restriction and Multiple Sclerosis Prevention**

---

### *Dietary restriction in MS prevention in murine models*

Virtually all chronic CR studies in mouse MS model have shown effects on prevention and not treatment, possibly because cycles of the combination of restriction and re-feeding as well as the severity, type and length of the restriction, not simply chronic CR optimizes the effects on MS pathology and symptoms. Chronic moderate to severe CR (33-60%) has been shown to promote protective effects in the prevention of EAE in various MS models<sup>84,85</sup>. After chronic CR, 33% or 40% of mice showed a minor decrease in the EAE induction and disease severity but were protected from EAE induced inflammation, demyelination, and axon injury<sup>84,85</sup>. Interestingly, only severe CR (66% caloric restricted group) completely prevented EAE induction<sup>84,85</sup>. Similarly, a chronic ketogenic diet, consisting of a 4:1 ratio of fat to carbohydrate and protein<sup>86</sup>, has been reported to serve as a preventive measure against EAE<sup>87</sup>. However, similar to the effect of chronic moderate CR, KD did not completely prevent the EAE disease induction but reduced the severity of the disease<sup>87</sup>. Intermittent fasting (IF), where fasting is applied every other day, was also shown to improve EAE disease severity<sup>88</sup>. Eight weeks of IF prior to the EAE immunization completely protected mice from EAE induction compared to 75% incident rate of *ad libitum* group<sup>88</sup>. Although the exact mode of these protective effects are still under active investigation, these dietary interventions showed similar changes in immune response including a significant reduction in circulating and CNS-derived CD4<sup>+</sup> and CD8<sup>+</sup> T cells and CD11b<sup>+</sup>CD45<sup>+</sup> cells (macrophages and microglia) compared to the control diet group, and markedly reduced cytokines (IL-1 $\beta$ , IL-6, TNF- $\alpha$ , IL-12, IL-17) and chemokines (IFN- $\gamma$ , MCP-1, MIP-1 $\alpha$ , MIP-1 $\beta$ )<sup>84,85,87,88</sup>.

### **Fasting Mimicking Diets as a Treatment for MS and Other Autoimmunities**

#### *Fasting and murine MS models*

---

Some of the major limitations of the chronic dietary restrictions listed above are: 1) that they would be very difficult to adopt for the great majority of the population, 2) that they can cause both protective and detrimental effects including impaired immune responses and would healing, 3) that they are effective in the prevention but not treatment of MS. Furthermore, these dietary interventions fail to address one of the core aspects of MS treatment, which is the need to stimulate both the regeneration of functional white blood cells and the remyelination at the demyelinated lesions either by stimulating myelin production or regenerating oligodendrocyte from oligodendrocyte precursor cells. Periodic treatment with a fasting mimicking diet (FMD) with a very low calorie and protein content has the potential to overcome the limitations listed above. FMD cycles were shown to attenuate EAE symptoms by modulating immune cells and promoting oligodendrocyte precursor cell regeneration<sup>89</sup>. This study showed that a periodic fasting mimicking dietary intervention has potent MS treatment effects in mice but also that it has the potential to minimize side effects as well as compliance issues. FMD cycles not only resulted in a reduction in dendritic cells which are known to play an important role as antigen presenting cells (APC) that secrete cytokines responsible for activating T lymphocytes, but also reduced circulating MOG<sub>35-55</sub> specific CD4<sup>+</sup> T cells, Th1 and Th17 cells and reduced serum cytokines such as IFN- $\gamma$ , IL-17 and TNF- $\alpha$ . Furthermore, the FMD treatment increased anti-inflammatory CD4<sup>+</sup> Treg. It was previously shown that during the cycles of the prolonged fasting, the immune cells undergo system-wide apoptosis followed by hematopoietic stem cell based regeneration upon re-introduction of nutrients (re-feeding period) in IGF-1-PKA dependent manner<sup>21</sup>. Similarly, FMD cycles cause apoptosis of autoreactive T cells, which are replaced by newly generated naïve T cells during re-feeding period<sup>89</sup> (**Fig. 2**). More importantly,

the FMD treatments promoted oligodendrocyte precursor cell dependent regeneration of oligodendrocyte, which is known to participate in remyelination of demyelinated axons.

#### *Dietary restrictions in human clinical trials*

In a human clinical trial, a 7-day cycle of a FMD followed by 6 months of a Mediterranean diet, was reported to be safe and feasible<sup>89</sup>. A chronic KD intervention also resulted in potentially positive effects on relapse-remitting MS (RRMS) patients. Moreover, both the FMD and the chronic KD were associated with positive changes in self-reported Health-Related Quality of Life (HRQoL) and an improvement in Expanded Disability Status Scales (EDSS) compared to what was reported by the control diet group. Similar to the rodent study, the clinical trial also reports a reduction in lymphocyte upon FMD intervention which indicates that the diet may work in a similar manner in mice and humans. However, whether or not FMD cycles will reduce MS incidence in humans is still unclear and must be tested in larger randomized clinical trials. One of the possible mechanisms of the FMD-dependent modulation of autoimmunity involves the up-regulation of serum glucocorticoid, adiponectin and the reduction of IL-6 and leptin<sup>84</sup>. RRMS patient had significantly higher leptin and resistin levels and lower levels of adiponectin and Treg cells<sup>42</sup>. Therefore, PF and FMDs may stimulate endogenous production of glucocorticoid, adiponectin that may contribute to a system-wide suppression of specific immune responses.

### **3.2 Autoimmune Diabetes**

Type 1 diabetes is an autoimmune disease commonly diagnosed in children and young adults, leading to the destruction of the insulin-producing pancreatic beta cell in the islets of Langerhans leading to a lack of insulin production<sup>90,91</sup>. Type I diabetes is associated with the

infiltration of innate and adaptive immune cells that produce cytokines which promote beta cell apoptosis and increase infiltration of islet-specific T cells. Infiltrating T cells, predominantly CD4<sup>+</sup> or CD8<sup>+</sup>, play an important role in the induction type 1 diabetes mellitus<sup>92,93</sup>. Studies using human and murine models of diabetes have demonstrated that the destructive autoimmune process in type 1 diabetes requires both CD4<sup>+</sup> and CD8<sup>+</sup> T cells and macrophages<sup>94,95</sup>. Although DR has been widely studied for the prevention and treatment for type 2 diabetes, the effect of different forms of DR in autoimmune type 1 diabetes is poorly understood.

#### *Dietary restriction in Diabetes Type 1 murine models*

Studies have shown that CR improves glycemic homeostasis and reduces oxidative stress and lipid peroxidation in streptozotocin (STZ)-induced type 1 diabetic (T1D) rats model<sup>96-98</sup>. Chronic CR (30% reduction in daily caloric intake) for 9 weeks prior to STZ-induced diabetes showed a protection against diabetic insults<sup>99</sup>. CR inhibits up-regulation of inflammatory cytokines (IL-1 $\beta$ , IL-4, and IL-6) and TNF- $\alpha$ , activates IL-10 and haptoglobin in the plasma of streptozotocin-induced diabetic rats<sup>99</sup>. IF, performed for 30 days from 5 p.m. to 8 a.m., minimized the increase in pancreatic, hepatic and renal weight, which is commonly observed in the STZ-treated rats<sup>100</sup>. IF improved glucose tolerance, insulin sensitivity and percentage of apoptotic B cells in the pancreas of STZ-induced diabetic rats<sup>100</sup>. Moreover, an alteration in the dietary protein content has been shown to exacerbate diabetes. High-protein diet accelerated the onset of disease in spontaneous autoimmune models are the non-obese diabetic (NOD) mice<sup>101</sup>. It was shown that the types of dietary protein have a major impact on the incidence of diabetes in the NOD mouse. NOD mice fed with meat or casein result in an early onset of the disease while mice fed with casein hydrolysate, a denatured form, or lactalbumin-based diet was relatively protected against the disease<sup>102,103</sup>.

---

Recently, cycles of FMD were shown to promote the reprogramming of pancreatic islet cells, leading to the induction of a gene expression profile with similarities to that observed during fetal development and able to reverse insulin deficiency in mouse models of Type 1 and Type 2 diabetes (Cheng et al, *Cell*, in press). Fasting mimicking conditions also reversed insulin deficiency defects in human cells derived from autoimmune type 1 diabetes patients, indicating that FMD has the potential to treat human diabetes.

Thus, we are only beginning to understand the relationship between nutrition and the autoimmunity related to T1D. However, FMD cycles appear to have high potential for the treatment of both Type 1 and Type 2 diabetes. In fact, a recent pilot study showed a long-lasting reduction in fasting glucose in subjects who completed 3 monthly cycles of the FMD, although it is not known whether this effect involves pancreatic regeneration<sup>17</sup>. Additional animal and randomized studies are needed to confirm these results and serve as the foundation for dietary FDA approved treatments for autoimmune diabetes.

### 3.3 Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease, characterized by synovial hyperplasia, production of autoantibody, destruction of cartilage and bone and malformation and destruction of multiple joints<sup>104,105</sup>. The pathogenesis of RA is complicated involving both genetic and external factors<sup>106</sup>. Similar to other autoimmune disease, RA involves an aberrant pathway of T cell activation in both the initial and progression phases of the disease<sup>107,108</sup>. However, it has become clear that pathogenesis of RA cannot simply be explained in terms of a classical antigen-driven expansion of effector T cells, but that disease progression involves a more complex autoimmune response. It is largely accepted that RA is closely associated with CD4<sup>+</sup> T effector cells (both Th-1, 2, 17) which can be detected in RA synovial joints<sup>109-112</sup>.

Moreover, patients with RA have a premature immune aging phenotype including accumulation of CD4<sup>+</sup> CD28<sup>-</sup> T cells, telomeric shortening in hematopoietic stem cells, proliferation defects of naïve CD4 T cells, premature loss of naïve CD4 T cells telomeres, loss of telomerase in T cells, and impaired DNA damage repair due to ATM insufficiency<sup>113</sup>. Different dietary interventions have been shown to or have the potential to attenuate and possibly reverse the symptoms of RA.

#### *Dietary restriction in RA patients*

Fasting has been actively integrated as an alternative therapy for RA and a number of clinical trials has been conducted to test its efficacy<sup>114-117</sup>. Fifty-three RA patients were randomly grouped into either a control diet or fasting group in which subjects underwent fasting only once for a period ranging from 7 to 10 days followed by a vegan diet for 3.5 months<sup>115</sup>. Patients in the fasting group reported a significant improvement in all clinical parameters and half of the laboratory parameters such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) that are correlated with RA disease severity<sup>115</sup>. In a similar study, twenty RA patients were subjected to either a control or fasting (7 to 10 days) period followed by a strict vegan diet. Patients in the fasting group reported significantly less pain and an improvement in symptoms<sup>118</sup>. Thus, either periodic fasting or FMD have the potential to treat RA, although larger randomized studies are necessary to test this possibility. It will be important to test the effect of cycles of FMD that are applied every 1-2 months on RA patients, with or without the need to undergo drastic dietary changes, which are unlikely to be feasible for the majority of patients.

### **3.4 Conclusion**

We are now just beginning to understand the complex connections between metabolism and the regulation of T cells in relation to autoimmune diseases development and progression. In the

development of novel therapeutics for autoimmune disorders, targeting T cell metabolism by dietary interventions provides an alternative way to control T cell fate and function<sup>119</sup>. CR or various other dietary restrictions and particularly relatively long-term fasting, and FMDs cycles followed by re-feeding appear to decrease the biological rate of aging and promote anti-inflammatory effects, and may contribute to alleviate and possibly reverse a variety of autoimmune disorders as well as immunosenescence by killing old and damaged cells and replacing them with young and functional ones. However, the limited number of studies and of participants in studies described in this review, underlines the need for a set of larger randomized clinical trials testing both the feasibility and efficacy of FMDs, fasting and other DR-based interventions on the treatment of autoimmunities.

In summary, chronic CR and other chronic dietary restrictions have shown some efficacy in the prevention but not the treatment of autoimmunities. Thus, chronic CR and other DRs have the potential to prevent many age-related diseases, including autoimmunity, possibly by delaying aging. However, chronic CR is associated with poor compliance and long-term studies in monkeys indicate that diet composition, in addition to the restriction, may have a key role in disease prevention<sup>57,63</sup>. In contrast, PF and FMD cycles followed by refeeding are emerging as both effective and feasible interventions with the potential for long-term and wide use. They are also emerging as powerful interventions in the treatment of other age-related diseases and conditions including immunosenescence. The ability of periodic cycles of PF/FMD to suppress autoimmune cells and the ability of the re-feeding phase to help repair the damaged sites, and to activate hematopoietic cells to provide healthy immune cells indicate that they stimulate highly sophisticated repair and regenerative programs with similarities to those activated during development (**Fig. 2**). Notably, the periodic PF/FMD combines a period of severe restriction

sufficiently long to promote the death of a significant portion of damaged cells with a period of high nourishment re-feeding able to promote the opposite effect on growth and other factors leading to multi-system regeneration. These programs, which may have been frequently activated under the normal conditions in which famine periods were commonly encountered, may remain dormant in individuals constantly exposed to food intake and in which fasting periods lasting for over a few days are virtually absent.

## References

- 1 Franceschi, C. & Campisi, J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *The journals of gerontology. Series A, Biological sciences and medical sciences* **69 Suppl 1**, S4-9, doi:10.1093/gerona/glu057 (2014).
- 2 Franceschi, C. *et al.* Inflamm-aging. An evolutionary perspective on immunosenescence. *Annals of the New York Academy of Sciences* **908**, 244-254 (2000).
- 3 Yan, J. *et al.* The effect of ageing on human lymphocyte subsets: comparison of males and females. *Immun Ageing* **7**, 4, doi:10.1186/1742-4933-7-4 (2010).
- 4 Coder, B. D., Wang, H., Ruan, L. & Su, D. M. Thymic involution perturbs negative selection leading to autoreactive T cells that induce chronic inflammation. *J Immunol* **194**, 5825-5837, doi:10.4049/jimmunol.1500082 (2015).
- 5 Britanova, O. V. *et al.* Age-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling. *J Immunol* **192**, 2689-2698, doi:10.4049/jimmunol.1302064 (2014).
- 6 Denking, M. D., Leins, H., Schirmbeck, R., Florian, M. C. & Geiger, H. HSC Aging and Senescent Immune Remodeling. *Trends in immunology* **36**, 815-824, doi:10.1016/j.it.2015.10.008 (2015).
- 7 Geiger, H., de Haan, G. & Florian, M. C. The ageing haematopoietic stem cell compartment. *Nature reviews. Immunology* **13**, 376-389, doi:10.1038/nri3433 (2013).
- 8 Lee, C. & Longo, V. Dietary restriction with and without caloric restriction for healthy aging. *F1000Research* **5**, doi:10.12688/f1000research.7136.1 (2016).
- 9 Fontana, L. & Partridge, L. Promoting health and longevity through diet: from model organisms to humans. *Cell* **161**, 106-118, doi:10.1016/j.cell.2015.02.020 (2015).
- 10 Fontana, L., Partridge, L. & Longo, V. D. Extending healthy life span--from yeast to humans. *Science* **328**, 321-326, doi:10.1126/science.1172539 (2010).
- 11 Chaix, A., Zarrinpar, A., Miu, P. & Panda, S. Time-restricted feeding is a preventative and therapeutic intervention against diverse nutritional challenges. *Cell metabolism* **20**, 991-1005, doi:10.1016/j.cmet.2014.11.001 (2014).

- 12 Gill, S., Le, H. D., Melkani, G. C. & Panda, S. Time-restricted feeding attenuates age-related  
cardiac decline in *Drosophila*. *Science* **347**, 1265-1269, doi:10.1126/science.1256682 (2015).
- 13 Hatori, M. *et al.* Time-restricted feeding without reducing caloric intake prevents metabolic  
diseases in mice fed a high-fat diet. *Cell metabolism* **15**, 848-860,  
doi:10.1016/j.cmet.2012.04.019 (2012).
- 14 Miller, R. A. *et al.* Methionine-deficient diet extends mouse lifespan, slows immune and lens  
aging, alters glucose, T4, IGF-I and insulin levels, and increases hepatocyte MIF levels and stress  
resistance. *Aging cell* **4**, 119-125, doi:10.1111/j.1474-9726.2005.00152.x (2005).
- 15 Mirzaei, H., Raynes, R. & Longo, V. D. The conserved role of protein restriction in aging and  
disease. *Current opinion in clinical nutrition and metabolic care* **19**, 74-79,  
doi:10.1097/MCO.000000000000239 (2016).
- 16 Mirzaei, H., Suarez, J. A. & Longo, V. D. Protein and amino acid restriction, aging and disease:  
from yeast to humans. *Trends in endocrinology and metabolism: TEM* **25**, 558-566,  
doi:10.1016/j.tem.2014.07.002 (2014).
- 17 Brandhorst, S. *et al.* A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration,  
Enhanced Cognitive Performance, and Healthspan. *Cell Metab* **22**, 86-99,  
doi:10.1016/j.cmet.2015.05.012 (2015).
- 18 Nikolich-Zugich, J. & Messaoudi, I. Mice and flies and monkeys too: caloric restriction  
rejuvenates the aging immune system of non-human primates. *Exp Gerontol* **40**, 884-893,  
doi:10.1016/j.exger.2005.06.007 (2005).
- 19 Tang, D. *et al.* Dietary restriction improves repopulation but impairs lymphoid differentiation  
capacity of hematopoietic stem cells in early aging. *The Journal of experimental medicine* **213**,  
535-553, doi:10.1084/jem.20151100 (2016).
- 20 Mihaylova, M. M., Sabatini, D. M. & Yilmaz, O. H. Dietary and metabolic control of stem cell  
function in physiology and cancer. *Cell stem cell* **14**, 292-305, doi:10.1016/j.stem.2014.02.008  
(2014).
- 21 Cheng, C. W. *et al.* Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-  
based regeneration and reverse immunosuppression. *Cell stem cell* **14**, 810-823,  
doi:10.1016/j.stem.2014.04.014 (2014).
- 22 MacIver, N. J., Michalek, R. D. & Rathmell, J. C. Metabolic regulation of T lymphocytes. *Annual  
review of immunology* **31**, 259-283, doi:10.1146/annurev-immunol-032712-095956 (2013).
- 23 Pearce, E. L. Metabolism in T cell activation and differentiation. *Current opinion in immunology*  
**22**, 314-320, doi:10.1016/j.coi.2010.01.018 (2010).
- 24 Chehtane, M. & Khaled, A. R. Interleukin-7 mediates glucose utilization in lymphocytes through  
transcriptional regulation of the hexokinase II gene. *American journal of physiology. Cell  
physiology* **298**, C1560-1571, doi:10.1152/ajpcell.00506.2009 (2010).
- 25 Swainson, L. *et al.* IL-7-induced proliferation of recent thymic emigrants requires activation of  
the PI3K pathway. *Blood* **109**, 1034-1042, doi:10.1182/blood-2006-06-027912 (2007).
- 26 Macintyre, A. N. *et al.* The glucose transporter Glut1 is selectively essential for CD4 T cell  
activation and effector function. *Cell metabolism* **20**, 61-72, doi:10.1016/j.cmet.2014.05.004  
(2014).
- 27 Ardawi, M. S. Glutamine and glucose metabolism in human peripheral lymphocytes. *Metabolism:  
clinical and experimental* **37**, 99-103 (1988).
- 28 Carr, E. L. *et al.* Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK  
during T lymphocyte activation. *Journal of immunology* **185**, 1037-1044,  
doi:10.4049/jimmunol.0903586 (2010).

- 29 Nakaya, M. *et al.* Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. *Immunity* **40**, 692-705, doi:10.1016/j.immuni.2014.04.007 (2014).
- 30 Sinclair, L. V. *et al.* Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. *Nature immunology* **14**, 500-508, doi:10.1038/ni.2556 (2013).
- 31 Wang, R. *et al.* The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. *Immunity* **35**, 871-882, doi:10.1016/j.immuni.2011.09.021 (2011).
- 32 Ananieva, E. A., Patel, C. H., Drake, C. H., Powell, J. D. & Hutson, S. M. Cytosolic branched chain aminotransferase (BCATc) regulates mTORC1 signaling and glycolytic metabolism in CD4+ T cells. *The Journal of biological chemistry* **289**, 18793-18804, doi:10.1074/jbc.M114.554113 (2014).
- 33 Kopf, H., de la Rosa, G. M., Howard, O. M. & Chen, X. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. *International immunopharmacology* **7**, 1819-1824, doi:10.1016/j.intimp.2007.08.027 (2007).
- 34 Delgoffe, G. M. *et al.* The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. *Immunity* **30**, 832-844, doi:10.1016/j.immuni.2009.04.014 (2009).
- 35 Zeng, H. *et al.* mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. *Nature* **499**, 485-490, doi:10.1038/nature12297 (2013).
- 36 Ostroukhova, M. *et al.* The role of low-level lactate production in airway inflammation in asthma. *American journal of physiology. Lung cellular and molecular physiology* **302**, L300-307, doi:10.1152/ajplung.00221.2011 (2012).
- 37 Wahl, D. R. *et al.* Characterization of the metabolic phenotype of chronically activated lymphocytes. *Lupus* **19**, 1492-1501, doi:10.1177/0961203310373109 (2010).
- 38 Yin, Y. *et al.* Normalization of CD4+ T cell metabolism reverses lupus. *Science translational medicine* **7**, 274ra218, doi:10.1126/scitranslmed.aaa0835 (2015).
- 39 Frigo, M., Cogo, M. G., Fusco, M. L., Gardinetti, M. & Frigeni, B. Glutamate and multiple sclerosis. *Current medicinal chemistry* **19**, 1295-1299 (2012).
- 40 Sarchielli, P., Greco, L., Floridi, A., Floridi, A. & Gallai, V. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. *Archives of neurology* **60**, 1082-1088, doi:10.1001/archneur.60.8.1082 (2003).
- 41 Tisell, A. *et al.* Increased concentrations of glutamate and glutamine in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans. *PLoS one* **8**, e61817, doi:10.1371/journal.pone.0061817 (2013).
- 42 Kraszula, L. *et al.* Evaluation of the relationship between leptin, resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosis. *Neurologia i neurochirurgia polska* **46**, 22-28 (2012).
- 43 Yang, Z., Fujii, H., Mohan, S. V., Goronzy, J. J. & Weyand, C. M. Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells. *The Journal of experimental medicine* **210**, 2119-2134, doi:10.1084/jem.20130252 (2013).
- 44 Saulot, V. *et al.* Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. *Arthritis and rheumatism* **46**, 1196-1201, doi:10.1002/art.10252 (2002).
- 45 Ukaji, F. *et al.* Serum samples of patients with rheumatoid arthritis contain a specific autoantibody to "denatured" aldolase A in the osteoblast-like cell line, MG-63. *Annals of the rheumatic diseases* **58**, 169-174 (1999).
- 46 Schaller, M., Burton, D. R. & Ditzel, H. J. Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. *Nature immunology* **2**, 746-753, doi:10.1038/90696 (2001).

- 47 Boraschi, D. *et al.* The gracefully aging immune system. *Science translational medicine* **5**,  
185ps188, doi:10.1126/scitranslmed.3005624 (2013).
- 48 Valenzuela, H. F. & Effros, R. B. in *Bone Marrow Lymphoid Infiltrates* 17-34 (Springer, 2012).
- 49 Frasca, D. & Blomberg, B. B. Aging affects human B cell responses. *J Clin Immunol* **31**, 430-435,  
doi:10.1007/s10875-010-9501-7 (2011).
- 50 Cannizzo, E. S., Clement, C. C., Sahu, R., Follo, C. & Santambrogio, L. Oxidative stress, inflamm-  
aging and immunosenescence. *Journal of proteomics* **74**, 2313-2323,  
doi:10.1016/j.jprot.2011.06.005 (2011).
- 51 Sansoni, P. *et al.* Lymphocyte subsets and natural killer cell activity in healthy old people and  
centenarians. *Blood* **82**, 2767-2773 (1993).
- 52 Vescovini, R. *et al.* Naive and memory CD8 T cell pool homeostasis in advanced aging: impact of  
age and of antigen-specific responses to cytomegalovirus. *Age (Dordr)* **36**, 625-640,  
doi:10.1007/s11357-013-9594-z (2014).
- 53 Douek, D. C. *et al.* Changes in thymic function with age and during the treatment of HIV  
infection. *Nature* **396**, 690-695, doi:10.1038/25374 (1998).
- 54 Hasler, P. & Zouali, M. Immune receptor signaling, aging, and autoimmunity. *Cell Immunol* **233**,  
102-108, doi:10.1016/j.cellimm.2005.04.012 (2005).
- 55 Goronzy, J. J. & Weyand, C. M. Immune aging and autoimmunity. *Cellular and molecular life  
sciences : CMLS* **69**, 1615-1623, doi:10.1007/s00018-012-0970-0 (2012).
- 56 Rosenblum, M. D., Remedios, K. A. & Abbas, A. K. Mechanisms of human autoimmunity. *The  
Journal of clinical investigation* **125**, 2228-2233, doi:10.1172/JCI78088 (2015).
- 57 Mattison, J. A. *et al.* Impact of caloric restriction on health and survival in rhesus monkeys from  
the NIA study. *Nature* **489**, 318-321, doi:10.1038/nature11432 (2012).
- 58 Longo, V. D. & Mattson, M. P. Fasting: molecular mechanisms and clinical applications. *Cell  
Metab* **19**, 181-192, doi:10.1016/j.cmet.2013.12.008 (2014).
- 59 Yu, B. P., Masoro, E. J., Murata, I., Bertrand, H. A. & Lynd, F. T. Life span study of SPF Fischer 344  
male rats fed ad libitum or restricted diets: longevity, growth, lean body mass and disease.  
*Journal of gerontology* **37**, 130-141 (1982).
- 60 Goodrick, C. L., Ingram, D. K., Reynolds, M. A., Freeman, J. R. & Cider, N. Effects of intermittent  
feeding upon body weight and lifespan in inbred mice: interaction of genotype and age.  
*Mechanisms of ageing and development* **55**, 69-87 (1990).
- 61 Jiang, J. C., Jaruga, E., Repnevskaya, M. V. & Jazwinski, S. M. An intervention resembling caloric  
restriction prolongs life span and retards aging in yeast. *FASEB journal : official publication of the  
Federation of American Societies for Experimental Biology* **14**, 2135-2137, doi:10.1096/fj.00-  
0242fje (2000).
- 62 Sohal, R. S. & Weindruch, R. Oxidative stress, caloric restriction, and aging. *Science* **273**, 59-63  
(1996).
- 63 Colman, R. J. *et al.* Caloric restriction reduces age-related and all-cause mortality in rhesus  
monkeys. *Nat Commun* **5**, 3557, doi:10.1038/ncomms4557 (2014).
- 64 Lee, C. & Longo, V. D. Fasting vs dietary restriction in cellular protection and cancer treatment:  
from model organisms to patients. *Oncogene* **30**, 3305-3316, doi:10.1038/onc.2011.91 (2011).
- 65 Du, K., Herzig, S., Kulkarni, R. N. & Montminy, M. TRB3: a tribbles homolog that inhibits Akt/PKB  
activation by insulin in liver. *Science* **300**, 1574-1577, doi:10.1126/science.1079817 (2003).
- 66 Sans, M. D., Lee, S. H., D'Alecy, L. G. & Williams, J. A. Feeding activates protein synthesis in  
mouse pancreas at the translational level without increase in mRNA. *American journal of  
physiology. Gastrointestinal and liver physiology* **287**, G667-675, doi:10.1152/ajpgi.00505.2003  
(2004).

- 67 Imae, M., Fu, Z., Yoshida, A., Noguchi, T. & Kato, H. Nutritional and hormonal factors control the gene expression of FoxOs, the mammalian homologues of DAF-16. *Journal of molecular endocrinology* **30**, 253-262 (2003).
- 68 Safdie, F. M. *et al.* Fasting and cancer treatment in humans: A case series report. *Aging* **1**, 988-1007 (2009).
- 69 Lee, C., Raffaghello, L. & Longo, V. D. Starvation, detoxification, and multidrug resistance in cancer therapy. *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy* **15**, 114-122, doi:10.1016/j.drup.2012.01.004 (2012).
- 70 Lee, C. *et al.* Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. *Science translational medicine* **4**, 124ra127, doi:10.1126/scitranslmed.3003293 (2012).
- 71 Yang, Z., Matteson, E. L., Goronzy, J. J. & Weyand, C. M. T-cell metabolism in autoimmune disease. *Arthritis research & therapy* **17**, 29, doi:10.1186/s13075-015-0542-4 (2015).
- 72 Friese, M. A. & Fugger, L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? *Brain : a journal of neurology* **128**, 1747-1763, doi:10.1093/brain/awh578 (2005).
- 73 Pender, M. P. & Greer, J. M. Immunology of multiple sclerosis. *Current allergy and asthma reports* **7**, 285-292 (2007).
- 74 Rasmussen, S. *et al.* Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing--remitting experimental autoimmune encephalomyelitis. *Brain : a journal of neurology* **130**, 2816-2829, doi:10.1093/brain/awm219 (2007).
- 75 Sospedra, M. & Martin, R. Immunology of multiple sclerosis. *Annual review of immunology* **23**, 683-747, doi:10.1146/annurev.immunol.23.021704.115707 (2005).
- 76 Dhib-Jalbut, S. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. *Neurology* **68**, S13-21; discussion S43-54, doi:10.1212/01.wnl.0000275228.13012.7b (2007).
- 77 Fletcher, J. M., Lalor, S. J., Sweeney, C. M., Tubridy, N. & Mills, K. H. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. *Clinical and experimental immunology* **162**, 1-11, doi:10.1111/j.1365-2249.2010.04143.x (2010).
- 78 Hemmer, B., Archelos, J. J. & Hartung, H. P. New concepts in the immunopathogenesis of multiple sclerosis. *Nature reviews. Neuroscience* **3**, 291-301, doi:10.1038/nrn784 (2002).
- 79 Goverman, J. Autoimmune T cell responses in the central nervous system. *Nature reviews. Immunology* **9**, 393-407, doi:10.1038/nri2550 (2009).
- 80 Benveniste, E. N. & Benos, D. J. TNF-alpha- and IFN-gamma-mediated signal transduction pathways: effects on glial cell gene expression and function. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* **9**, 1577-1584 (1995).
- 81 Chang, A., Tourtellotte, W. W., Rudick, R. & Trapp, B. D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. *The New England journal of medicine* **346**, 165-173, doi:10.1056/NEJMoa010994 (2002).
- 82 Wolswijk, G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **18**, 601-609 (1998).
- 83 Wingerchuk, D. M. & Carter, J. L. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. *Mayo Clinic proceedings* **89**, 225-240, doi:10.1016/j.mayocp.2013.11.002 (2014).
- 84 Piccio, L., Stark, J. L. & Cross, A. H. Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis. *Journal of leukocyte biology* **84**, 940-948, doi:10.1189/jlhb.0208133 (2008).

- 85 Esquifino, A. I., Cano, P., Jimenez, V., Cutrera, R. A. & Cardinali, D. P. Experimental allergic encephalomyelitis in male Lewis rats subjected to calorie restriction. *Journal of physiology and biochemistry* **60**, 245-252 (2004).
- 86 DeVivo, D. C., Leckie, M. P., Ferrendelli, J. S. & McDougal, D. B., Jr. Chronic ketosis and cerebral metabolism. *Annals of neurology* **3**, 331-337, doi:10.1002/ana.410030410 (1978).
- 87 Kim do, Y. *et al.* Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. *PLoS one* **7**, e35476, doi:10.1371/journal.pone.0035476 (2012).
- 88 Kafami, L. *et al.* Intermittent feeding attenuates clinical course of experimental autoimmune encephalomyelitis in C57BL/6 mice. *Avicenna journal of medical biotechnology* **2**, 47-52 (2010).
- 89 Choi, I. Y. *et al.* A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms. *Cell reports*, doi:10.1016/j.celrep.2016.05.009 (2016).
- 90 King, A. J. The use of animal models in diabetes research. *British journal of pharmacology* **166**, 877-894, doi:10.1111/j.1476-5381.2012.01911.x (2012).
- 91 Hyttinen, V., Kaprio, J., Kinnunen, L., Koskenvuo, M. & Tuomilehto, J. Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. *Diabetes* **52**, 1052-1055 (2003).
- 92 Hanninen, A. *et al.* Macrophages, T cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. *The Journal of clinical investigation* **90**, 1901-1910, doi:10.1172/JCI116067 (1992).
- 93 Conrad, B. *et al.* Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. *Nature* **371**, 351-355, doi:10.1038/371351a0 (1994).
- 94 Yoon, J. W. & Jun, H. S. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. *Annals of the New York Academy of Sciences* **928**, 200-211 (2001).
- 95 Wong, F. S. & Janeway, C. A., Jr. The role of CD4 and CD8 T cells in type I diabetes in the NOD mouse. *Research in immunology* **148**, 327-332 (1997).
- 96 Anson, R. M. *et al.* Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. *Proceedings of the National Academy of Sciences of the United States of America* **100**, 6216-6220, doi:10.1073/pnas.1035720100 (2003).
- 97 Mattson, M. P. & Wan, R. Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems. *The Journal of nutritional biochemistry* **16**, 129-137, doi:10.1016/j.jnutbio.2004.12.007 (2005).
- 98 Wegge, J. K., Roberts, C. K., Ngo, T. H. & Barnard, R. J. Effect of diet and exercise intervention on inflammatory and adhesion molecules in postmenopausal women on hormone replacement therapy and at risk for coronary artery disease. *Metabolism: clinical and experimental* **53**, 377-381 (2004).
- 99 Ugochukwu, N. H. & Figgers, C. L. Caloric restriction inhibits up-regulation of inflammatory cytokines and TNF-alpha, and activates IL-10 and haptoglobin in the plasma of streptozotocin-induced diabetic rats. *The Journal of nutritional biochemistry* **18**, 120-126, doi:10.1016/j.jnutbio.2006.03.008 (2007).
- 100 Belkacemi, L. *et al.* Intermittent fasting modulation of the diabetic syndrome in streptozotocin-injected rats. *International journal of endocrinology* **2012**, 962012, doi:10.1155/2012/962012 (2012).
- 101 Schneider, K., Laube, H. & Linn, T. A diet enriched in protein accelerates diabetes manifestation in NOD mice. *Acta diabetologica* **33**, 236-240 (1996).


- 102 Beales, P. E. *et al.* A multi-centre, blinded international trial of the effect of A(1) and A(2) beta-casein variants on diabetes incidence in two rodent models of spontaneous Type I diabetes. *Diabetologia* **45**, 1240-1246, doi:10.1007/s00125-002-0898-2 (2002).
- 103 Elliott, R. B., Reddy, S. N., Bibby, N. J. & Kida, K. Dietary prevention of diabetes in the non-obese diabetic mouse. *Diabetologia* **31**, 62-64 (1988).
- 104 Harris, E. D., Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. *The New England journal of medicine* **322**, 1277-1289, doi:10.1056/NEJM199005033221805 (1990).
- 105 Firestein, G. S. Mechanisms of tissue destruction and cellular activation in rheumatoid arthritis. *Current opinion in rheumatology* **4**, 348-354 (1992).
- 106 Symmons, D. P. Environmental factors and the outcome of rheumatoid arthritis. *Best practice & research. Clinical rheumatology* **17**, 717-727 (2003).
- 107 VanderBorgh, A., Geusens, P., Raus, J. & Stinissen, P. The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. *Seminars in arthritis and rheumatism* **31**, 160-175, doi:10.1053/sarh.2001.27736 (2001).
- 108 Cope, A. P., Schulze-Koops, H. & Aringer, M. The central role of T cells in rheumatoid arthritis. *Clinical and experimental rheumatology* **25**, S4-11 (2007).
- 109 Yudoh, K., Matsuno, H., Nakazawa, F., Yonezawa, T. & Kimura, T. Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. *Arthritis and rheumatism* **43**, 617-627, doi:10.1002/1529-0131(200003)43:3<617::AID-ANR19>3.0.CO;2-B (2000).
- 110 Chabaud, M. *et al.* Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. *Arthritis and rheumatism* **42**, 963-970, doi:10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E (1999).
- 111 Ronnelid, J. *et al.* Production of T-cell cytokines at the single-cell level in patients with inflammatory arthritides: enhanced activity in synovial fluid compared to blood. *British journal of rheumatology* **37**, 7-14 (1998).
- 112 Kanik, K. S. *et al.* Distinct patterns of cytokine secretion characterize new onset synovitis versus chronic rheumatoid arthritis. *The Journal of rheumatology* **25**, 16-22 (1998).
- 113 Weyand, C. M., Yang, Z. & Goronzy, J. J. T-cell aging in rheumatoid arthritis. *Curr Opin Rheumatol* **26**, 93-100, doi:10.1097/BOR.000000000000011 (2014).
- 114 Muller, H., de Toledo, F. W. & Resch, K. L. Fasting followed by vegetarian diet in patients with rheumatoid arthritis: a systematic review. *Scandinavian journal of rheumatology* **30**, 1-10 (2001).
- 115 Kjeldsen-Kragh, J. *et al.* Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis. *Lancet* **338**, 899-902 (1991).
- 116 Skoldstam, L., Larsson, L. & Lindstrom, F. D. Effect of fasting and lactovegetarian diet on rheumatoid arthritis. *Scandinavian journal of rheumatology* **8**, 249-255 (1979).
- 117 Darlington, L. G., Ramsey, N. W. & Mansfield, J. R. Placebo-controlled, blind study of dietary manipulation therapy in rheumatoid arthritis. *Lancet* **1**, 236-238 (1986).
- 118 Skoldstam, L. Fasting and vegan diet in rheumatoid arthritis. *Scandinavian journal of rheumatology* **15**, 219-221 (1986).
- 119 O'Sullivan, D. & Pearce, E. L. Immunology. Expanding the role of metabolism in T cells. *Science* **348**, 976-977, doi:10.1126/science.aac4997 (2015).

**Table 1. Calorie and Dietary restriction**

Types		Definition	Duration	Ref
Calorie Restriction (CR)		20 – 40% Reduction in total calorie intake	Chronic	<sup>1,2</sup>
Dietary Restriction	Ketogenic Diet (KD)	High-fat, low-carbohydrate diet. In human, diets with caloric contents of up to 75-80% fat and $\geq$ 15% protein are commonly used to treat various neurological disorders.	Chronic	<sup>3</sup>
	Fasting/Prolonged Fasting (PF) / Intermittent Fasting (IF)/ Alternative Day Feeding (ADF)	Fasting: Complete absence of food intake. PF refers to at least 2 and usually 3 or more consecutive fasting days, which can be repeated periodically. IF and ADF eliminate or greatly reduce daily intake of food/calories intermittently (usually every other day or every 2-3 days). Usually ADF refers to alternation of a day of feeding and a day of either water only fasting or a very low calorie diet.	Periodic PF: 2 or more days / 2-4 weeks  IF/ADF: 1 day on 1 day off	<sup>4,5</sup>
	Fasting mimicking diet (FMD)	Formulations composition of macronutrients and micronutrients specifically formulated to trigger responses such as reduced glucose and insulin-like growth factor 1 (IGF-1) level, and increased ketone bodies, while maximizing caloric intake	Periodic (2-7 days every 15 to 365 days)	<sup>6</sup>

- 1 Hursting, S. D., Lavigne, J. A., Berrigan, D., Perkins, S. N. & Barrett, J. C. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. *Annu Rev Med* **54**, 131-152, doi:10.1146/annurev.med.54.101601.152156 (2003).
- 2 Longo, V. D. & Fontana, L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. *Trends Pharmacol Sci* **31**, 89-98, doi:10.1016/j.tips.2009.11.004 (2010).
- 3 Schugar, R. C. & Crawford, P. A. Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. *Curr Opin Clin Nutr Metab Care* **15**, 374-380, doi:10.1097/MCO.0b013e3283547157 (2012).
- 4 Mattson, M. P. *et al.* Meal frequency and timing in health and disease. *Proc Natl Acad Sci U S A* **111**, 16647-16653, doi:10.1073/pnas.1413965111 (2014).
- 5 Longo, V. D. & Mattson, M. P. Fasting: molecular mechanisms and clinical applications. *Cell Metab* **19**, 181-192, doi:10.1016/j.cmet.2013.12.008 (2014).
- 6 Brandhorst, S. *et al.* A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. *Cell Metab* **22**, 86-99, doi:10.1016/j.cmet.2015.05.012 (2015).


**Figure 1**



**Figure 1. Change in metabolism of the activated T cells and autoimmune T cells**

Metabolism plays an important role in T cell proliferation and differentiation and dysregulation of metabolism is often linked to autoimmune diseases. Upon activation, T cells primarily use aerobic glycolysis and produce lactate as a byproduct to support biosynthetic precursors that required for cellular proliferation. Increased lactate and abnormal glycolytic pathway are frequently observed in T cells from asthma and rheumatoid arthritis patients. During activation, T cells increase the expression of glutamine transporters and glutamate metabolism to support T cell proliferation and differentiation. Interestingly, the increased levels of glutamate and glutamine are observed at the site of demyelination and axonal degeneration in MS patients. Mammalian target of rapamycin (mTOR) promotes activation and differentiation of the T effector cells, and down-regulates Treg differentiation. Also, the Akt-mTOR axis act as a negative regulator of Treg cells. Activation of mTORC1 promotes glycolysis through hypoxia-induced factor 1 $\alpha$  (HIF1  $\alpha$ ), and dysregulation of mTOR is frequently observed in MS patients. These changes in metabolism provide an unique opportunity to target for disease treatment purposes.

**Figure 2**



**Figure 2. FMD-dependent modulation of autoimmunity and tissue-specific regeneration of damaged cells.**

FMD causes a systemic anti-inflammatory effect and specific suppression of autoimmune cells whereas the re-feeding period stimulates hematopoietic cells to generate naïve cells to replace the immune cells eliminated. FMD also promotes tissue-specific stem cells that repair the damaged sites.

## HIGHLIGHTS

- Dietary restrictions and fasting decrease immunosenescence.
  - Fasting or Fasting mimicking diet promotes anti-inflammatory effects.
  - Fasting mimicking diet alleviates or reverses autoimmune disorders in mice and possibly humans.
- s